
Zoetis
-2.62 %
-5.9 %
Yet to be announced
Company Overview
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts.
Revenue Sources
PassAfter analyzing Zoetis's business model and revenue sources, the company's primary revenue streams come from animal health products and services, including medicines, vaccines, diagnostics and related technologies. None of these products or services are inherently haram. The company does not derive significant revenue from pork, alcohol, gambling, or other prohibited sources.
Reliance on Interest
Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
---|---|---|---|---|---|---|
Sept. 30, 2024 | $2.39b | $1.53b | - | $57.0m | 0.00% | 3.73% |
June 30, 2024 | $2.36b | $1.56b | - | $59.0m | 0.00% | 3.79% |
March 31, 2024 | $2.19b | $1.45b | - | $58.0m | 0.00% | 4.00% |
Dec. 31, 2023 | $2.21b | $1.57b | - | $59.0m | 0.00% | 3.76% |
Based on the financial data provided for the last four quarters, Zoetis's interest expense represents a small portion of its total expenses. The interest expense ratios for the past four quarters have consistently remained below the 5% threshold that would indicate material reliance on interest-bearing debt.
Operational Ethics
PassBased on available information from SEC filings and company disclosures, while Zoetis operates globally, there is no evidence of significant ongoing associations with entities involved in human rights violations. The company maintains standard business operations in various countries but does not appear to have material ties to the state of Israel or direct involvement with the Chinese Communist Party.
Login to join the discussion